| Autor: |
Gianfrancesco M; Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA., Hyrich KL; Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK., Yazdany J; Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA., Machado PM; MRC Centre for Neuromuscular Diseases, University College London, London, UK.; Rheumatology, University College London Centre for Rheumatology, London, UK., Robinson PC; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia philip.robinson@uq.edu.au.; Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia. |
| Abstrakt: |
Competing Interests: Competing interests: MG reports grants from National Institutes of Health, NIAMS, outside the submitted work; KLH reports she has received speaker’s fees from Abbvie and grant income from BMS, UCB and Pfizer, all unrelated to this manuscript. KLH is also supported by the NIHR Manchester Biomedical Research Centre; JY reports personal fees from Astra Zeneca, personal fees from Eli Lilly, grants from Pfizer, outside the submitted work; PMM reports personal fees from Abbvie, personal fees from Eli Lilly, personal fees from Novartis, personal fees from UCB, outside the submitted work. PCR reports personal fees from Abbvie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche, UCB Pharma and non-financial support from BMS and Roche, outside the submitted work. |
